ANALOGUES OF CYSTAMINE, USED FOR PARKINSON'S DISEASE TREATMENT Russian patent published in 2017 - IPC A61K31/185 A61K31/198 A61P25/16 

FIELD: medicine.

SUBSTANCE: application of a therapeutically effective amount of at least one cysteamine analog, namely cysteamine and cystamine or a pharmaceutically acceptable salt thereof, for Parkinson's disease treatment at stage II, III or IV according to the Hoehn and Yahr classification, and wherein the cystamine analog or a pharmaceutically acceptable salt thereof is used as: a) an agent for functional restoration of damaged neurons; and/or b) an agent for the structural repair of damaged neurons. Application of a combination comprising at least one cystamine analogue and cysteine or salts thereof for treatment of Parkinson's disease in a patient with Parkinson's disease symptoms, and application of a pharmaceutical composition comprising at least one cystamine analogue or pharmaceutically acceptable salts thereof and containing cysteine or pharmaceutically acceptable salt thereof for treatment of Parkinson's disease in a patient with Parkinson's disease symptoms, is proposed.

EFFECT: functional and structural repair of damaged dopaminergic neurons with cysteamine or cystamine and increased number of nerve cells axons in the damaged areas, cysteine significantly increases cysteamine absorption by the brain.

16 cl, 12 dwg